Methotrexate dosage regimen in biological trials in RA
| Author (year) | Biologic | MTX maximum dose (mg/week) | MTX mean dose (mg/week) | MTX route of administration |
|---|---|---|---|---|
| Bathon et al (2000) | ETN | 20 | 19 | Oral |
| Lee et al (2014) | TOFA | 20 | 19 | Oral |
| Breedveld et al (2006) | ADA | 20 | 17 | Oral |
| Burmester et al (2015) | TCZ | 20 | 19 | Oral |
| Detert et al (2013) | ADA | 15 | 15 | Subcutaneous |
| Durez et al (2008) | INF | 20 | 20 | Oral |
| Emery et al (2008) | ETN | 20 | NR | Oral |
| Emery et al (2009) | GLM | 20 | 19 | Oral |
| Jones et al (2009) | TCZ | 20 | 16 | Oral |
| Smolen et al (2014) | ADA | 20 | NR | Oral |
| St Clair et al (2004) | INF | 20 | 15 | Oral |
| Tak et al (2010) | RTX | 20 | >18 | Oral |
| Westhovens et al (2009) | ABA | 20 | 19 | Oral* |
*In the Westhovens et al trial 1.5% of subjects received injectable MTX, but it was not part of the protocol.
ABA, abatacept; ADA, adalimumab; CZP, certolizumab; ETN, etanercept; GLM, golimumab; INF, infliximab; MTX, methotrexate; NR, not reported; RA, rheumatoid arthritis; RTX, rituximab; SC, subcutaneous; TCZ, tocilizumab; TOFA, tofacitinib.